Abstract: Amplification of the epidermal growth factor receptor (EGFR) gene is one of the most common oncogenic alterations in glioblastoma (45%) making it a prime target for therapy. However, small molecule inhibitors of the EGFR tyrosine kinase showed disappointing efficacy in clinical trials for glioblastoma.
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Purpose
Amplification of the epidermal growth factor receptor (EGFR) gene is a common oncogenic alteration in glioblastoma making it a prime target for therapy. However, small molecule inhibitors of the EGFR tyrosine kinase failed in clinical trials for glioblastoma.
Here we aimed at investigating the molecular effects of preoperative treatment with the tyrosine kinase inhibitor gefitinib on the EGFR signalling pathway in glioblastoma tissue.
Patients and Methods
In a phase II trial, 22 patients selected for re-operation of recurrent glioblastoma were treated at least 5 days with 500 mg gefitinib prior to surgery, followed by post-operative gefitinib until recurrence. Resected glioblastoma tissues were tested for drug concentrations and EGFR-pathway activity using phosphorylation specific assays.
Results

Glioblastoma tissues exhibited high concentrations of gefitinib (median, 4,100 ng/g). The
EGFR was efficiently dephosphorylated in treated patients as compared to a control cohort of 12 patients. However, downstream pathway constituents did not seem to be 
Conclusion
Gefitinib reaches high concentrations in the tumor tissue and efficiently dephosphorylates its target. However, regulation of downstream signal transducers in the EGFR pathway seems to be dominated by regulatory circuits independent of EGFR phosphorylation.
INTRODUCTION
The epidermal growth factor receptor (EGFR) offers a particularly attractive target in glioblastoma therapy, since it is overexpressed in 60% of glioblastoma usually associated with high level amplification of the EGFR gene. Small molecule drugs have been developed to specifically target the catalytic kinase domain of the EGFR to prevent downstream signaling 1 . In NSCLC particularly good response was associated with mutations in the EGFR located around the ATP-binding pocket 2, 3 . In glioblastoma, however, such mutations have not been found 4 . Some missense mutations have been identified in the extracellular domain of a fraction of cases (14%) with potentially activating properties 5 , and were usually associated with amplification of the locus. The most common alteration (20%), is the truncation mutant lacking exons 2 to 7 (EGFRvIII) affecting the extra cellular domain involved in dimerization and ligand binding that has been associated with constitutive phosphorylation of the receptor conferring an oncogenic potential 6, 7 .
A first publication 8 on a phase II trial testing the EGFR-inhibitor gefitinib in recurrent glioblastoma reported that response to treatment was not correlated with expression of the EGFR, although the authors have not excluded insufficient drug penetration of the tumor. As in most clinical trials for glioblastoma, enzyme inducing antiepileptic drugs (EIAEDs) were allowed in this study that have been shown to reduce systemic availability of the small molecule inhibitors of the EGFR 9 . In the meantime further phase II trials have been reported testing erlotinib or gefitinb in recurrent or progressive glioblastoma, summarized in Yung et al. 10 , or in newly diagnosed glioblastoma as addition to combined chemo-radiotherapy with temozolomide 11 , overall with disappointing efficacy.
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The occasional responses observed in these trials incited several studies to search for predictive molecular markers in the diagnostic tissue of the initial surgery that would allow future patient selection (reviewed in Brandes et al. 12 ). Several sets of markers with predictive value for response to therapy were proposed, comprising expression of EGFR, amplification of the EGFR gene, lack of elevated levels of AKT phosphorylation, and absence of EGFRvIII expression 13 , while another study suggested better response of tumors with expression of EGFRvIII and expression of PTEN 14 . The markers proposed in these small studies could not be confirmed in subsequent trials, including a randomized phase II trial 9 , although low p-AKT showed a trend for association with better outcome. The difficulty to successfully target one of the most common activated oncogenic pathways operative in glioblastoma has drastically revealed the complexity of the regulation of receptor tyrosine kinase (RTK) signaling that requires further investigations.
Here we present a phase II clinical trial designed to elucidate potential reasons for the unexpected low response rates of glioblastoma to EGFR inhibitors in previous clinical studies, by addressing the following questions: (i) does the drug reach the tumor across the blood-tumor barrier, (ii) is the EGFR dephosphorylated by the drug, and (iii) what are the effects on downstream signaling. To this end, patients selected for surgery for recurrent glioblastoma were offered participation in a trial with the EGFR inhibitor gefitinib, comprising 5 day pre-operative treatment, followed by postoperative treatment until recurrence or undue side effect. The translational research design included molecular profiling of the human glioblastoma samples obtained from the patients enrolled, and a control set. These efforts were complemented by an experimental in vitro and in vivo model using a tumorigenic glioblastoma cell line with an endogenous EGFR 4 amplification and expression of EGFRvIII to aid interpretation of the "noisy" data obtained from human tumors, where no before and after therapy sampling is possible. 
PATIENTS AND METHODS
Patients
Drug concentrations
Frozen tumor tissue and plasma samples were sent to the Laboratory Analytico Medinet B.V. (Breda, NL) to quantify the concentration of gefitinib by high performance liquid chromatography coupled to tandem mass spectrometry as described previously 15 ,16 .
The gefitinib concentrations in the BS-153 xenografts and the mouse plasma were determined at the quantitative Mass Spectrometry Facility (qMSF) at the Lausanne University Hospital using the same technology with minor modifications. The tumor tissue homogenates were prepared at 200 mg of wet weight/ml in phosphate buffer using a Fast Prep homogenizer (MP biomedicals, Basel, Switzerland).
Cell line and xenograft model
The human glioblastoma cell line BS-153 that comprises an amplified EGFR and expresses the mutant EGFRvIII 
Tissue Micro Array, Fluorescence In Situ Hybridization (FISH) and
Immunohistochemistry (IHC)
A tissue micro array (TMA) was constructed from paraffin embedded tumor blocks available from patients and the xenografts in nude mice derived from the human cell line BS-153. FISH for determination of EGFR copy number was performed and scored as described previously 9 . The EGFR copy number was normalized by a centromeric probe on chromosome 12 (CEP12). Immunohistochemical investigations were carried out according to standard procedures for paraffin sections using a heat induced epitope retrieval technique (HIER) in citrate buffer (pH 6.0; pressure cooker, 3-5 min) and overnight incubation with the primary antibody. The following antibodies were used, pmTOR (1:50, CellSignaling), PTEN (1:50, CellSignaling), CycD (1:50, Upstate). The immunostaining was scored semi-quantitatively (scores, 0-3).
Real-Time Quantitative polymerase chain reaction (qPCR)
DNA and RNA were isolated from frozen tissue using the Qiagen AllPrep DNA/RNA Kit (Qiagen, 80204). DNA from paraffin sections was isolated as described before 18 . The EGFR gene copy number was determined on DNA isolated from macro-dissected ). The following total proteins were determined, tot-ERK1/2 (#171-V32238), tot-p38MAPK (#171-V31336), tot-EGFR, tot-MEK1, and tot-AKT. Tot-ERK1/2 was present on all plates and was used for normalization of the data-set after log 2 -transformation.
Statistical Methods
Statistical significance of differences between treatments was evaluated with a non- days (range 5 to 150 days) with 500 mg gefitinib daily prior to surgery, followed by postoperative gefitinib until recurrence. The study outline is depicted in Fig. S1 . Central review confirmed recurrent glioblastoma in all cases. For three cases no frozen tissue became available, and several cases had to be excluded for molecular analysis, because the available frozen tissue consisted of >80% necroses or showed only reactive changes. Samples considered for further analysis had to display >50% compact viable tumor tissue (Table 1) .
EGFR amplification status
EGFR amplification was identified in 7 of 22 (32%) patients in the gefitinib group and 7 of 12 (58%) patient samples of the control group, as determined by FISH on the TMA and/or by qPCR from whole tumor sections (Table 1 Expression of the EGFRvIII was detectabled in two glioblastoma with an amplified EGFR status. (Fig. 1) 
Gefitinib concentrations in tumor tissue and plasma
The median concentration of gefitinib in the tumor tissue was 4,100 ng/g (range 16 to 26,000 ng/g), while the respective median concentration in the plasma was more than 20x lower 181 ng/ml (4 to 483 ng/ml) (p<0.0001). The median time laps between the last drug dose and collection of the tumor tissue and the blood sample was 5 h and 5 h 30 min, respectively. One patient did not take the drug on the day of surgery, reflected in very low drug concentrations in the tumor and the blood, respectively (Fig. 2) . Timed information was only recorded in one center, however, drug concentrations suggested a similar timeframe for tissue and blood collection for the other patients. The mean gefitinib concentration in the mouse BS-153 xenografts (n=9) was 1,669 ng/g (range, 457 to 3,620 ng/g) and 226 ng/ml (range, 65-336 ng/ml) in the serum (n=4). The tumors were harvested 4h after the last gavage of drug.
Patient outcome
The median survival after initiation of gefitinib treatment was 8.8 months. No difference was observed between patients with an amplified or a normal EGFR status.
However, patients whose resected tissue had to be excluded for molecular analysis due to predominantly necrotic tissue had longer survival (logrank, P=0.004). This may be an indication of pseudo-progression. However, the small patient numbers preclude proper analysis and interpretation of this observation.
Molecular analysis of the EGFR signalling pathway in glioblastoma
In order to investigate the effect of gefitinib on activation of the EGFR and respective downstream signaling, a phosphorylation screen for a selected panel of 12 published EGFR pathway signal transductors was performed. Beside pEGFR, it included constituents such as pAKT, pERK1/2 or pS6RP to cover distinct aspects of the pathway.
Further, it included PDGFR-B and SRC two important players in glioblastoma. PDGFR-B activates elements of the same pathway, while SRC has to been reported to be an effector of EGFR signaling 23 . Comparison between treated and untreated patients revealed that there was a border line significant decrease of phosphorylation of the EGFR (p=0.053), and surprisingly an increase of p-ERK1/2 phosphorylation (p=0.076).
The phosphorylation of the other signaling transductors were not significantly changed.
When stratifying for the EGFR amplification status, there was a significant reduction of EGFR phosphorylation (p=0.006), indicating efficient dephosphorylation by gefitinib as indicated by box plots in Figure 3A . Further, a trend for increased phosphorylation of ERK1/2 (p=0.104) was observed (Fig. 3B) . The statistical analysis for all phosphoproteins is summarized in Table S1 and the respective box plots are displayed in Fig.   S2 . The overall difference between treated and untreated patient samples did not reach statistical significance (p=0.139, Monte-Carlo test, 999 permutations, Fig. 3C ), thus the gefitinib treatment effect seems to be mostly restricted to dephosphorylation of the EGFR. Exclusion of 4 cases from the analysis who did not adhere strictly to the protocol, such as extended pre-treatment period (3 cases), or missed drug intake on the day of surgery (1 case) did not reveal other significant factors.
An interaction map of the pathway, indicating the analyzeded proteins, and a heatmap of the phosphorylation profiles are shown in Fig. 4 . The dendrogram from this unsupervised analysis suggests that EGFR signaling was not dominating the activity of the pathway. In fact EGFR phosphorylation was least related to pathway activation as indicated by principal component analysis (PCA) of all measured phospho-proteins (Fig.   4C ). The closest correlation was with pPDGFR-B (Pearson correlation r=0.5) (Fig. S3, shows all pairwise comparisons), however, the amplitude of pPDGFR-B was much lower (Fig. S3,4) . Information on expression of PTEN, CycD and p-mTOR was obtained by immunohistochemistry on the respective TMA, included as label to the heatmap (Fig.   4B ).
Effect of gefitinib on EGFR signaling pathway in an in vitro and in vivo model
In parallel to the human clinical trial we investigated gefitinib modulation of EGFR signaling in an in vitro and in vivo model to facilitate interpretation of the human data.
The human glioblastoma cell line BS-153, with inherent amplification and overexpression of the EGFR and overexpression of the mutant EGFRvIII (Fig 1, 5) , was subjected to gefitinib treatment in vitro and in vivo. In vitro experiments carried out over 24 h showed as expected dephosphorylation of the EGFRwt&vIII, and also reduced phosphorylation of key signal transductors, such as AKT that is involved in cell survival signaling, and p90RSK a regulator of cell growth and differentiation ( (Table S1 ). This is counterintuitive, since a decrease if anything would have been expected according to the interaction map of the pathway. The overall inertness of the pathway signal transductors to EGFR dephosphorylation by gefitinib may not surprise given our observation that EGFR phosphorylation was not indicative of overall activation of the pathway regardless of the treatment (Fig. 4C) . It has been proposed that the signaling network, constituted by the ERBB family of receptors of which EGFR is a member (ERBB1), and other mitogenic receptors involved in the malignant behavior of glioblastoma such as MET, or PDGFR, is very robust, since it shares modularity (parts of the pathway), and shows redundancy of regulatory circuits Moreover, respective analysis at resection likely shows a snapshot of a newly established steady state. In addition, in vitro systems lack stress signaling induced in vivo by metabolic stress, or hypoxia that share some of the downstream signal transductors.
In conclusion, the present study suggests that the EGFR inhibitor gefitinib reaches the tumor in high concentrations, efficiently dephosphorylates the target, however, this does not suffice to control pathway activity. EGFR-phosphorylation independent regulatory circuits seem to dominate the pathway. In order to find therapeutic opportunities, the fragilities of the network need to be enquired that may help to design promising combination therapies for patients with respective molecular 18 (82) 3 (14) 1 ( T0 A0  T1 A1  T1 A0  T0 A1  T0 A0  T1 A1  T1 A0  T0 A1   A  B   T0_A0  T1_A1  T1_A0  T0_A1  T0_A0  T1_A1  T1_A0 and euclidean distance. The dataset is normalized by total-Erk1/2, but neither scaled
